NASDAQ:REPL Replimune Group (REPL) Stock Price, News & Analysis $13.43 +0.43 (+3.31%) As of 12:04 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Replimune Group Stock (NASDAQ:REPL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Replimune Group alerts:Sign Up Key Stats Today's Range$12.65▼$13.6650-Day Range$5.35▼$15.9852-Week Range$1.50▼$16.33Volume517,556 shsAverage Volume4.54 million shsMarket Capitalization$1.26 billionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingModerate Buy Company Overview Replimune Group, Inc. is a biotechnology company focused on developing oncolytic immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company’s approach is based on a proprietary platform that uses genetically engineered herpes simplex virus type 1 (HSV-1) to selectively replicate in tumors and deliver immune-activating payloads. Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an investigational oncolytic immunotherapy being evaluated in clinical studies for solid tumors, including melanoma and cutaneous squamous cell carcinoma. The company is also developing additional candidates, including RP2 and RP3, which are designed to incorporate further immune-stimulating mechanisms and potentially address a broader range of cancers. Founded in 2015 and headquartered in Woburn, Massachusetts, Replimune conducts research and clinical development activities through collaborations and trials involving patients in the United States and other international markets. The company’s leadership has included co-founder and Chief Executive Officer Philip Astley-Sparke, who has experience in biotechnology and oncology-focused drug development.AI Generated. May Contain Errors. Read More Replimune Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreREPL MarketRank™: Replimune Group scored higher than 29% of companies evaluated by MarketBeat, and ranked 775th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingReplimune Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 2 sell ratings.Downside RiskReplimune Group has a consensus price target of $12.00, representing about 10.6% downside from its current price of $13.43.Amount of Analyst CoverageReplimune Group has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Replimune Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Replimune Group are expected to grow in the coming year, from ($2.81) to ($2.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 6.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Replimune Group's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.64% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 11.14, which indicates bearish sentiment.Change versus previous monthShort interest in Replimune Group has recently decreased by 3.25%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.25 News SentimentReplimune Group has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Replimune Group this week, compared to 7 articles on an average week.Search InterestOnly 1 people have searched for REPL on MarketBeat in the last 30 days. This is a decrease of -96% compared to the previous 30 days.MarketBeat Follows4 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,038,364.00 in company stock.Percentage Held by Insiders5.40% of the stock of Replimune Group is held by insiders.Percentage Held by Institutions92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Replimune Group's insider trading history. Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REPL Stock News HeadlinesREPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5thSeptember 29 at 5:17 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPLSeptember 29 at 4:30 PM | globenewswire.comA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before September 30, pointing to a critical shift ahead for tech and AI-related stocks.September 30 at 1:00 AM | TradeSmith (Ad)REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact SueWallStSeptember 29 at 10:13 AM | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. InvestorsSeptember 29 at 9:00 AM | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor HarmSeptember 28 at 12:00 PM | globenewswire.comREPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact Levi & KorsinskySeptember 28 at 10:14 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPLSeptember 24, 2026 | prnewswire.comSee More Headlines REPL Stock Analysis - Frequently Asked Questions How have REPL shares performed this year? Replimune Group's stock was trading at $9.72 on January 1st, 2026. Since then, REPL shares have increased by 38.2% and is now trading at $13.43. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) issued its earnings results on Friday, August, 14th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by $0.03. When did Replimune Group IPO? Replimune Group (REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Replimune Group investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Home Depot (HD). Company Calendar Last Earnings8/14/2026Today9/30/2026Next Earnings (Estimated)11/05/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 REPL's financial health is in the Green zone, according to TradeSmith. REPL has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:REPL CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees465Year Founded2015Price Target and Rating Average Price Target for Replimune Group$12.00 High Price Target$21.00 Low Price Target$2.00 Potential Upside/Downside-10.4%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($3.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$313.94 million Net MarginsN/A Pretax MarginN/A Return on Equity-159.32% Return on Assets-90.84% Debt Debt-to-Equity Ratio1.00 Current Ratio5.23 Quick Ratio5.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book6.66Miscellaneous Outstanding Shares93,798,000Free Float88,733,000Market Cap$1.26 billion OptionableOptionable Beta0.94 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:REPL) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersDr. Ron Paul Issues New Warning: “The Next Financial Crisis Is Here”Dr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dol...Altimetry | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
